Kura Oncology (KURA) Equity Ratio (2010 - 2026)

Kura Oncology (KURA) has 17 years of Equity Ratio data on file, last reported at 0.17 in Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.17, down 66.26% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.17 (down 66.26% YoY), and the FY2025 annual result was 0.24, down 56.66% from the prior year.
• Equity Ratio eased to 0.17 in Q1 2026 per KURA's latest filing, from 0.24 in the prior quarter.
• Over five years, Equity Ratio peaked at 0.96 in Q1 2022 and troughed at 0.17 in Q1 2026.
• A 5-year average of 0.73 and a median of 0.9 in 2024 frame the typical range for Equity Ratio.
• The sharpest annual moves came in 2022 and 2026: Equity Ratio climbed 1.11% in 2022, then tumbled 66.26% in 2026.
• A 5-year view of Equity Ratio shows it stood at 0.92 in 2022, then retreated by 3.92% to 0.88 in 2023, then sank by 38.51% to 0.54 in 2024, then slumped by 56.66% to 0.24 in 2025, then decreased by 29.9% to 0.17 in 2026.
• Business Quant data shows KURA's Equity Ratio at 0.17 in Q1 2026, 0.24 in Q4 2025, and 0.37 in Q3 2025.